Brammer invests in commercial-ready gene therapies – BioPharma-Reporter.com
BioPharma-Reporter.com |
Brammer invests in commercial-ready gene therapies
BioPharma-Reporter.com The contract development and manufacturing organization (CDMO) said the site offers process development, clinical phase, and current Good Manufacturing Practices (cGMP) services for cell and gene therapies. “We are delighted to add an experienced … |
